Enterococcus Polypeptide Vaccine Targeting Peptidoglycan
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and prevention strategies for antibiotic-resistant Enterococci are inadequate, as existing vaccines and therapeutic approaches have not effectively targeted the cell surface structures of these bacteria, leading to untreatable life-threatening infections.
Innovation Solution
A polypeptide with a specific amino acid sequence (SEQ ID NO:1) is identified, which can be used to produce protective antibodies by eliciting neutralizing, opsonic, and complement-activating immune responses, potentially serving as a vaccine target against Enterococcus faecium and faecalis strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat Enterococci infections, then bacterial growth is inhibited, but antibiotic resistance develops and spreads rapidly
Solution Approach 1:
The invention segments the approach to treating Enterococci infections by moving from a single-mode antibiotic treatment to a dual-mode strategy combining traditional antibiotics with a novel vaccine-based preventive approach. The vaccine targets specific cell surface structures (peptidoglycan and associated proteins) to elicit protective antibodies, creating a segmented defense system that addresses both treatment and prevention separately, thereby reducing selective pressure for antibiotic resistance.
Solution Approach 2:
The invention introduces antibodies as an intermediary mechanism between the immune system and Enterococci bacteria. These antibodies specifically target cell surface structures including peptidoglycan and associated proteins, serving as a mediator that neutralizes bacterial infectivity and facilitates phagocytosis without directly killing the bacteria through antibiotic mechanisms, thus avoiding the development of antibiotic resistance.
2Adaptability or versatility
If existing vaccines target general bacterial components, then broad coverage is achieved, but specificity against cell surface structures like peptidoglycan is insufficient
Solution Approach 1:
The invention applies local quality by focusing the vaccine's protective effect on specific local structures of the Enterococci cell surface, particularly peptidoglycan and its associated proteins. Rather than attempting to target the entire bacterium uniformly, the vaccine is designed to specifically recognize and bind to these localized cell surface components, eliciting antibodies that provide targeted protection at the critical interface between the bacteria and the host.
Solution Approach 2:
The invention achieves universality by developing a vaccine platform that targets conserved cell surface structures (peptidoglycan and associated proteins) that are common across different Enterococci strains and species. This multi-functional approach allows a single vaccine formulation to provide broad coverage against various Enterococci pathogens while maintaining high specificity for these essential cell surface components.
3Ease of manufacture
If antibiotics are continued to be used despite resistance, then treatment options are maintained, but life-threatening infections become untreatable
Solution Approach 1:
The invention implements preliminary action by introducing a preventive vaccine that prepares the immune system in advance against Enterococci infections. By administering the vaccine before infection occurs, the host develops protective antibodies that specifically target cell surface structures, creating a pre-established defense mechanism that reduces reliance on antibiotics and maintains treatment effectiveness for when infections do occur.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide induces opsonic and protective antibodies that inhibit bacterial infectivity and facilitate phagocytosis, providing effective prevention and treatment against Enterococci infections, particularly in immunocompromised patients and hospital settings.
Implementation Method 1
Second, by coating the pathogens, said antibodies can enable accessory cells that recognize the Fc portions of arrays of antibodies to ingest and kill the pathogen. This process is called opsonisation.
Implementation Method 2
Third, antibodies can trigger the activation of the complement system. Complement proteins can strongly enhance opsonisation or can directly kill certain bacterial cells.
Implementation Method 3
Proteins belonging to this family may act as cell wall peptidases which degrade the peptidoglycan of the bacteria during growth and cell division.
Data Source
AI summary
A medicament for the treatment or the prevention of a bacterial infection is disclosed which contains a polypeptide having a contiguous sequence of at least six amino acids of SEQ ID NO:1. Said polypeptide can be used for the preparation of a vaccine against an Enterococcus infection.